CryoPort (NASDAQ:CYRX) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 0 | 3 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for CryoPort, revealing an average target of $18.4, a high estimate of $21.00, and a low estimate of $17.00. Surpassing the previous average price target of $18.12, the current average has increased by 1.55%.
Decoding Analyst Ratings: A Detailed Look
The perception of CryoPort by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yuan Zhi | B. Riley Securities | Lowers | Neutral | $19.00 | $22.00 |
| Matthew Stanton | Jefferies | Raises | Buy | $21.00 | $17.00 |
| John Sourbeer | UBS | Raises | Neutral | $17.00 | $14.50 |
| Jacob Johnson | Stephens & Co. | Maintains | Equal-Weight | $17.00 | - |
| David Saxon | Needham | Lowers | Buy | $18.00 | $19.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CryoPort. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CryoPort compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for CryoPort's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
For valuable insights into CryoPort's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on CryoPort analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind CryoPort
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
CryoPort's Economic Impact: An Analysis
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: CryoPort's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -5.13%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -112.45%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): CryoPort's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -13.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): CryoPort's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.58%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CryoPort's debt-to-equity ratio surpasses industry norms, standing at 0.9. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
How Are Analyst Ratings Determined?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.